SCHEMBL35211856

SCHEMBL35211856

CC[C@H]1CN(C(=O)OC(C)(C)C)[C@@H](C)c2c3cc(OC)c(Cl)c(F)c3nn21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLR9 Q9NR96 2/20 0.34
▸ PARP1 P09874 1/20 0.33
▸ SUV39H2 Q9H5I1 2/20 0.32
▸ KAT7 O95251 1/20 0.32
▸ RORC P51449 1/20 0.32
▸ TLR7 Q9NYK1 1/20 0.32
▸ CACNB4 O00305 1/20 0.31
▸ CACNA1A O00555 1/20 0.31
▸ CACNA1G O43497 1/20 0.31
▸ CACNG3 O60359 1/20 0.31
▸ CACNA1F O60840 1/20 0.31
▸ CACNA1H O95180 1/20 0.31
▸ CACNB3 P54284 1/20 0.31
▸ CACNA2D1 P54289 1/20 0.31
▸ CACNG7 P62955 1/20 0.31
▸ CACNA1B Q00975 1/20 0.31
▸ CACNA1D Q01668 1/20 0.31
▸ CACNB1 Q02641 1/20 0.31
▸ CACNG1 Q06432 1/20 0.31
▸ CACNB2 Q08289 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35212313 0.91 PARP1 (0.32) PARP1KAT7KAT8KAT6AKAT5
SCHEMBL35211815 0.90 SUV39H2 (0.35) TLR9SUV39H2CACNB4CACNA1ACACNA1G
SCHEMBL35212050 0.90 SUV39H2 (0.35) TLR9SUV39H2CACNB4CACNA1ACACNA1G
SCHEMBL35212051 0.90 SUV39H2 (0.35) TLR9SUV39H2CACNB4CACNA1ACACNA1G
SCHEMBL35212558 0.89 PARP1 (0.33) TLR9PARP1TLR7EHMT2PDE4A
SCHEMBL35212586 0.89 PARP1 (0.33) PARP1KAT7KAT8KAT6ACETP
SCHEMBL34466688 0.89 PARP1 (0.33) PARP1KAT7KAT8KAT6ACETP
SCHEMBL34466687 0.89 PARP1 (0.33) PARP1KAT7KAT8KAT6ACETP
SCHEMBL35212429 0.89 PARP1 (0.33) PARP1KAT7KAT8KAT6ACETP
SCHEMBL34465081 0.89 PARP1 (0.33) PARP1KAT7KAT8KAT6ACETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125383-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2026-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125383-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF CGAS, PRKG1, GMPS TLR9 3953/4885PARP1 230/4885SUV39H2 4809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback